Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System

Inclusion Criteria: * Males ≥ 18 years of age; * ECOG status of 0 - 2; * Signed informed consent; * HRLPC cohort (n=25): * Clinical diagnosis of HRLPC, defined as stage pT3a or Gleason score \>8 and/or pre-prostatectomy PSA \>20 ng/mL; * 2-5 months post-radical prostatectomy; * Treatment naïve (i.e. have not received any systemic and/or hormonal therapy since the time of their radical prostatectomy). * BCRLPC cohort (n=25): * Patients with localized prostate cancer (pathological stages pT2, pT3a, pT3b or pT4 with TNM N0 or N1 and M0 disease) who have clinical suspicion of biochemical recurrence following a radical prostatectomy; * Have been pre-authorized by insurance to undergo next generation imaging (NGI, such as Axumin® or PSMA PETCT) within the next 45 days or have already undergone NGI within the past 45 days; * Treatment naïve (i.e. have not received any systemic and/or hormonal therapy since the time of their radical prostatectomy). * NMCRPC cohort (n=25): * Patients with evidence of non-metastatic castration-resistant prostate cancer (i.e. localized prostate cancer patients with clinical symptoms of disease progression and/or evidence of a rising PSA following hormone therapy); * Have been pre-authorized by insurance to undergo NGI (i.e. Axumin® or PSMA PETCT) within the next 45 days or have already undergone NGI within the past 45 days; * Have not started a new therapy for the treatment of their castration-resistant prostate cancer. * Control c…